GILD vs NBIX
Figures are each company’s own, from its most recent annual filing; fiscal year ends differ. Both are classified by the SEC under Biological Products, (No Diagnostic Substances).
| Metric | GILDGILEAD SCIENCES, INC. | NBIXNEUROCRINE BIOSCIENCES INC |
|---|---|---|
| Revenue | $29.44B | $2.86B |
| Gross margin | 78.8% | 98.2% |
| Operating income | $10.02B | $619.10M |
| Operating margin | 34.0% | 21.6% |
| Net income | $8.51B | $478.60M |
| Net margin | 28.9% | 16.7% |
| Free cash flow | $9.46B | $748.70M |
| Total assets | $59.02B | $4.63B |
| Total equity | $22.62B | $3.25B |
| Diluted EPS | $6.78 | $4.67 |
Every figure links to the filing it came from on each company page: GILD and NBIX. See the methodology for how each one is chosen.